CytomX Therapeutics, Inc. (CTMX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 18,658 | 50,917 | 33,432 | |
| Research and development | 13,322 | 18,868 | 21,368 | |
| General and administrative | 6,622 | 9,428 | 7,953 | |
| Total operating expenses | 19,944 | 28,296 | 29,321 | |
| Income (loss) from operations | -1,286 | 22,621 | 4,111 | |
| Interest income | 1,178 | 955 | 1,693 | |
| Other (expense) income, net | 17 | 11 | -7 | |
| Income (loss) before income taxes | -91 | 23,587 | 5,797 | |
| Provision for income taxes | 63 | 62 | 61 | |
| Net income (loss) | -154 | 23,525 | 5,736 | |
| Unrealized (loss) gain on investments, net of tax | 34 | -28 | 44 | |
| Total comprehensive income (loss) | -120 | 23,497 | 5,780 | |
| Weighted average number of shares outstanding, basic | 129,075,546 | 87,121,502 | 85,093,227 | |
| Weighted average number of shares outstanding, diluted | 129,075,546 | 87,150,666 | 85,204,709 | |